What's Next For Amarin Investors?
It's been an emotional and financial rollercoaster for Amarin (NASDAQ:AMRN), with the hype surrounding Vascepa leaving investors deep underwater, gasping for air.
(click to enlarge)
Since attaining FDA approval for its lead product on July 26 last year, shares began and continued to tumble, with the negative FDA advisory committee panel meeting dealing a near coup de grace to the proverbial Pequod. Consequently, Amarin's high-profile failure has served to largely sour investors on companies with fish-oil or similar products. Enter Neptune Technologies & Bioresources (NASDAQ:NEPT), a similar company that is significantly de-risked and poised for double to triple digit returns over the next year.
Unless otherwise noted, financial statistics and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|